Australian authorities stopped pharmacies from making their own weight loss injections, and a South African outlet asks why its country hasn't followed.
Recap by typeshit. Post by Facebook on Facebook.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
A 2025 Kinsey Institute survey found more than half of users saw sex life changes, split both ways. Doctors quoted say solid causal evidence is still missing.
Sahpra reports about 600 fake medicine complaints this year, and new compounding rules aren't due until early next year, which industry head Stavros Nicolaou calls too late.
Loading…